|Bid||35.51 x 800|
|Ask||39.86 x 1000|
|Day's Range||38.03 - 39.46|
|52 Week Range||15.19 - 55.12|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 10, 2020 - Aug 14, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||44.75|
Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will participate in the following investor virtual conferences. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.
Drugmakers and biotech companies are initiating development of drugs, vaccines and therapies for COVID-19 and substantial progress has been made over the past month.
Professor of Medicine at Yale and Director of The Yale New Haven Hospital Center for Outcomes Research and Evaluation Dr. Harlan Krumholz joins Yahoo Finance’s Seana Smith to discuss Moderna’s recent headway in an early-stage coronavirus vaccine trial.
Ladies and gentlemen, thank you for standing by, and welcome to the Adaptive Biotechnologies first-quarter financial results conference call. Earlier today, Adaptive Biotechnologies released financial results for the first quarter ended March 31, 2020.
Investors have probably pretty much forgotten that Adaptive Biotechnologies (NASDAQ: ADPT) shares sank more than 40% earlier this year. Adaptive Biotechnologies announced first-quarter revenue of $20.9 million, a 65% jump from the $12.7 million reported in the same quarter of the previous year.
SEATTLE, May 12, 2020 -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the.
Adaptive Biotechnologies (ADPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
The U.S. death toll from the coronavirus that causes COVID-19 rose above 71,000 on Wednesday, as President Donald Trump appeared to back off his announcement that he would phase out the government task force created to manage the pandemic
A mix of legacy drugmakers and small startups have stepped forward with plans to develop vaccines or treatments that target the infection caused by the novel coronavirus.
The "ImmuneRace" study will genetically map the T-cells of 1,000 people who have been exposed to SARS-CoV-19.
Shares of Adaptive Biotechnologies Corp. were up 7.5% in premarket trading on Wednesday. The company on Tuesday had announced a virtual clinical study with Microsoft Corp. aimed at better understanding the immune response in 1,000 people who have tested positive for COVID-19 or have been exposed to the virus. The study will utilize diagnostic tests made by Laboratory Corporation of America Holdings , who will send employees to the participants' homes to collect the samples, which will then be used to examine patients' T-cells. Adaptive previously announced plans to work on an antibody program with Amgen that aims to develop a therapy that can prevent or treat COVID-19. Adaptive's stock is up 10.3% since the start of the year, while the S&P 500 is down 11.2%.
Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming BofA Securities Virtual Healthcare Conference. Adaptive Biotechnologies’ management is scheduled to present on Wednesday, May 13th at 12:00 p.m. Pactific Time / 3:00 p.m. Eastern Time.
Adaptive Biotechnologies Corp. (Nasdaq: ADPT) announced on Tuesday it has begun enrolling a virtual clinical study, ImmuneRACE, as part of a broader effort it has undertaken with Microsoft Corp. (Nasdaq: MSFT) to rapidly map and measure the immune response to the COVID-19 virus to inform improved diagnostics to fulfill the need for more reliable testing. The study calls for 1,000 participants in select U.S. metropolitan areas impacted by COVID-19. De-identified data will be made freely available to public health officials, academia and industry to help accelerate solutions to the pandemic. LabCorp (NYSE: LH), through its Covance drug development business, will manage the collection of blood samples and nose/throat swabs from participants in the comfort and safety of their own homes.
A large number of biotech companies have been working on developing drugs and vaccine for the novel coronavirus that has infected more than 3,100,000 and claimed 227,000 lives.
One company has a well-established line of products that made it the leader in its niche, but the other has a bold vision about how to use them.
SEATTLE, April 27, 2020 -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive.
Substantial progress has been made over the past few weeks with pharmaceutical companies speeding up development of coronavirus vaccines.
Basketball isn’t the first thing that springs to mind when considering the coronavirus, but according to BTIG’s Amanda Murphy, what we need right now is the “Michael Jordan” of COVID-19 antibodies.The analyst believes Adaptive Biotechnologies (ADPT) might just be the player with the mercurial abilities needed. The company has formed several alliances to fight COVID-19, and is tackling the virus from two different angles, both on the diagnostic and therapeutic front.On the diagnostic side, Adaptive has formed a number of partnerships to further research the immune system’s response to COVID-19. These include LabCorp, whose mobile phlebotomy capabilities can pick up samples from COVID-19 positive or recovered patients. LabCorp is also providing its CRO (contract research organization), Covance, to oversee the trial. Microsoft, which has contributed its AI platform, and Illumina, which is providing the technology to sequence the virus mapped to COVID-19 specific antigens identified by Adaptive's immunoSEQ Dx platform. Additionally, Providence, a large health system with 51 hospitals (including the one near Seattle that treated the first U.S. COVID-19 patient), is providing access to patients.Murphy believes the unprecedented amount of collaboration between the different companies could yield the much-needed quick response. The analyst argues that antibody-based testing will be vital in getting the country up and running again.“It is still unknown how many asymptomatic patients have undergone sero-conversion and would therefore test positive under standard serology testing. Thus, with the potential development timeline for an antibody-based test developed by Adaptive expressed in months (as opposed to years), the ability to generate a more intelligent and accurate immune response assay would be meaningfully impactful in getting things back “to normal,” the analyst said.Adaptive is also taking the fight to COVID-19 from a therapeutic angle. The company recently announced a collaboration with fellow biotech Amgen to identify neutralizing antibodies against COVID-19. “Adaptive is uniquely positioned with its platform to screen for B-cell receptors at the scale needed to identify neutralizing antibodies,” Murphy opined. Amgen’s experience of antibody development can then be used to develop therapeutics.All in all, Murphy reiterated a Buy on Adaptive along with a $46 price target, which represents an impressive 78.5% upside from current levels. (To watch Murphy’s track record, click here) More recent articles from Smarter Analyst: * Amazon Pilots Video Merchant Screening to ‘Block Bad Actors’ * RBC Capital Picks Pepsi Over Coca Cola Ahead of Q1 Earnings * Diamond Offshore Drilling Files For Chapter 11 Bankruptcy Amid Oil Crash * Domino’s Pizza Sees U.S. Comparable Sales Boost, Suspends Outlook
Wall Street continues to hold steady as traders and investors consider when and how the U.S. economy will reopen after weeks of disruption as the novel coronavirus outbreak changes the way Americans live, work, and play.When will non-essential businesses open? What is the timing on a treatment regime and vaccine? Will facemasks become the new normal? * 9 Asian Stocks to Buy for a Post-Coronavirus Recovery There are lots of questions with few answers. But one thing that's become abundantly clear is that there is a blitz of innovation underway as the health care industry ramps up its fight against Covid-19.InvestorPlace - Stock Market News, Stock Advice & Trading TipsA number of stocks in the industry are perking up nicely: * UnitedHealth Group (NYSE:UNH) * CVS Health Corp. (NYSE:CVS) * Cigna (NYSE:CI) * Amgen (NASDAQ:AMGN)So let's see what makes each of these an interesting stock to watch here. Healthcare Stocks to Buy: UnitedHealth Group (UNH)Source: Chart courtesy of StockCharts.comUNH shares are blasting off from the 50-day moving average, closing in on past highs just over the $300 level to cap a 50%+ rally off of late March lows. All of this is in the context of a three-year sideways range going back to late 2018. Shares are being fueled by better-than-expected earnings, bolstered by strength across its business lines.The nation's largest health insurer kept its 2020 outlook intact thanks in part to a lower-than-expected medical loss ratio of 81.0% of premiums paid versus estimates of 81.57%. Earnings clocked in at $3.72 per share, beating estimates of $3.63, on a 6.8% rise in revenues. Shares were recently upgraded by analysts at Deutsche Bank, who are looking for a price target of $308. CVS Health (CVS)Source: Chart courtesy of StockCharts.comCVS shares are rising off of double-bottom support near $50. The stock is now zooming back towards prior highs near $76 that have been tested time and again since the current trading range was established in late 2016.CVS has been at the center of a number of Covid-19 developments, thanks both to its 2018 acquisition of Aetna as well as its role as a national provider of drive-through testing services. * 9 Asian Stocks to Buy for a Post-Coronavirus Recovery The company reported strong Q4 2019 results back in February, with revenues up 22.9% for the quarter and 32% for the year. Earnings of $1.73 per share beat estimates by four cents. Q1 results will be reported on May 6, with earnings of $1.62 per share expected on revenues of $64.1 billion. Cigna (CI)Source: Chart courtesy of StockCharts.comCI shares are rallying strongly back towards triple-top resistance near the $225-a-share level capping a rise of more than 60% of its March lows. The company has been among the insurers waiving co-pays related to Covid-19 treatment and recently launched a pilot program to address loneliness as a result of social distancing and stay-at-home measures.Shares were recently updated by Raymond James ahead of the next earnings report on April 30 before the bell. Analysts are looking for earnings of $4.35 per share on revenues of $37.2 billion. When the company last reported on Feb. 6, earnings of $4.31 beat estimates by 11 cents on a 165.7% rise in revenues. Amgen (AMGN)Source: Chart courtesy of StockCharts.comAMGN shares are pushing back towards their previous high near $240, topping a rise of more than 30% from their recent low. The company recently announced a strategic partnership with Adaptive Biotech (NASDAQ:ADPT) to develop a treatment for COVID-19, either as a preventive or a cure.The company will next reports results after the close on April 30. Analysts are looking for earnings of $3.73 per share on revenues of just over $6 billion. * 9 Asian Stocks to Buy for a Post-Coronavirus Recovery When the company last reported earnings on Jan. 30, earnings of $3.64 per share beat estimates by 23 cents per share. Analysts at Guggenheim recently resumed coverage with a "neutral" rating.As of this writing, William Roth did not hold a position in any of the aforementioned securities. More From InvestorPlace * America's 1 Stock Picker Reveals Next 1,000% Winner * 25 Stocks You Should Sell Immediately * 1 Under-the-Radar 5G Stock to Buy Now * The 1 Stock All Retirees Must Own The post 4 Healthcare Stocks to Buy For Coronavirus Innovation appeared first on InvestorPlace.
If successful, the Sanofi (SNY) and GlaxoSmithKline plc (GSK) vaccine would be available in the second half of 2021. Shares of drugmakers jumped on the news.
Adaptive Biotechnologies (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the addition of two prominent hires to its executive leadership team. Mark Adams, Ph.D. has been appointed Chief Technical Officer to advance technology strategy across the company. Jyoti Palaniappan joins as Senior Vice President, Clinical Diagnostics, immunoSEQ Dx to establish the commercial infrastructure for the diagnostics pipeline resulting from our partnership with Microsoft.